IDX e-IPO Analytics

Thesis

PT Esa Medika Mandiri (EMMI) is a >20-year independent distributor of medical, laboratory and pharmaceutical devices — carrying global principals including Medtronic, Medicon, Bowa, Penlon and Air Liquide — with two light-manufacturing factories (Cikupa, Solo). The defining fact is concentration: roughly 96% of revenue (96.1% in 2025) goes to the government, and an even higher 98.5% of gross profit. Recent growth has been explosive but lumpy and margin-dilutive, funded by a heavily-geared balance sheet. The IPO is 100% primary, raising mostly working capital. It prices at a demanding trailing P/E, and a pre-IPO land revaluation has cosmetically improved how the leverage reads. This is a higher-risk name than its headline growth implies.

How the business works

EMMI is, in substance, a single operating company — the parent — with a cluster of near-zero subsidiaries (EBT, MMM, SUN, SSN, EWI) consolidated in 2023, contributing between 0.003% and 0.929% of revenue. It wins government and multilateral tenders, pre-funds the inventory and project goods, delivers, then carries long government receivables. There are no long-term sales contracts (a stated risk), so revenue is inherently lumpy. The 2024 surge was driven by specific named tenders rather than recurring demand: IsDB (Islamic Development Bank) tenders of Rp47.4 bn and a World Bank SOPHI tender of Rp101.7 bn, of which only ~20% (~Rp20 bn) was recognised in 2025. That leaves ~Rp81 bn of SOPHI revenue still to recognise — genuine near-term visibility — but beyond the current backlog, earnings depend entirely on winning fresh tenders, and a budget cut, lost tender or payment delay hits ~96% of the business.

The offering & ownership

The company offers 522,857,000 new shares (30% of post-IPO capital, all primary) at Rp446–Rp515 (par Rp50), with no selling shareholders and no greenshoe. Underwriting is full-commitment by PT BRI Danareksa Sekuritas (lead) and PT INA Sekuritas Indonesia — a credibility step up, with both declaring no affiliation to the issuer. The "Ina" overlap with lender Bank Ina Perdana is coincidental: INA Sekuritas is the former Nikko Sekuritas Indonesia, unrelated to Salim-group Bank Ina Perdana, so there is no underwriter-lender conflict.

Critically, there is no statutory POJK 25/2017 founder lock-up: the prospectus states no party acquired shares below the IPO price in the six months before registration, so the current structure (set by Akta No. 153, 23 Feb 2026) is treated as predating the window. The only restraint is Surya Gunawan Widjaja's 12-month commitment to retain control (≥50%) — which permits selling down toward 50%. The founder block is in principle freely tradable from listing day; this entire position hinges on the capital history genuinely predating the window and warrants verification. The ESA allots up to 52,285,700 shares (10% of offered / 3% post-IPO), including "Saham Penghargaan" reward shares carrying a notably long 30-month lock-up.

Governance & related parties

All owners are individuals — no holding company. Surya Gunawan Widjaja is the declared controller (UBO), and the Widjaja family holds 85% pre-IPO falling to 59% post-IPO. The governance item worth a careful read: the Independent Commissioner is a former senior Ministry of Health (Kemenkes) medical-device regulator — per the disclosed CV, Director of Medical Device & PKRT Assessment (2021–2024) and Director of Medical Device Supervision (2016–2021), now also leading a medical-device industry association. This is reproduced factually with no inference of wrongdoing. Analytically it cuts both ways: deep regulatory and tender expertise for a 96%-government supplier, against weakened substance of "independence" for a recent regulator of the exact products EMMI sells. Related-party items include building rental income of Rp2.61 bn (2025) and a joint venture contributing equity-method profit of Rp4.10 bn (2025) — roughly 12% of net profit, non-core income that flatters the bottom line and whose counterparty and durability merit confirmation.

Reading the financials

The trajectory is striking but qualified. Sales grew +122.5% in 2024 and +18.1% in 2025 to Rp454.64 bn, but the 2024 surge came with a gross-margin collapse from 51.3% to 35.3% (35.9% in 2025) — this is low-margin government volume, not premium product. Leverage is the second story: interest expense (Rp30.44 bn in 2025) consumed 247% of operating profit in 2023 and still 46% in 2025, the signature of a debt-funded model. Note that 2025 net profit attributable to parent (Rp34.13 bn) exceeds total profit (Rp32.44 bn) because non-controlling interests absorbed Rp1.69 bn of subsidiary losses — EPS must be struck on parent profit.

Working capital is structurally stretched: the current ratio was below 1.0 in every year (0.48× / 0.82× / 0.92×), with government receivable days lengthening to 110 in 2025. The structural item to flag is the Rp37.65 bn land revaluation of the Serpong HQ in 2025 — independently appraised and proper under PSAK 16, but non-cash. It lifted equity from Rp73.4 bn to Rp145.0 bn and cut reported liabilities/equity from 8.74× to 2.89× right before the IPO. Strip it out and DER is ~3.91× — the deleveraging is partly cosmetic, since the cash debt did not fall; the equity denominator was revalued up. The FY2024/2023 comparatives were also restated (disajikan kembali), superseding the earlier reports — the restatement reason should be read in the notes.

Valuation

At the range, the post-IPO market cap is Rp777.3 bn–Rp897.6 bn, putting EMMI on a ~22.8×–26.3× trailing P/E on 2025 parent profit. That is demanding for a ~96% government-concentrated, ~7% net-margin, heavily-leveraged, tender-dependent distributor — you are paying a growth multiple for earnings whose visibility past the SOPHI/IsDB backlog is low. Quality caveats compress the case: ~12% of net profit is JV equity income, book value (and therefore P/BV) is flattered by the land revaluation, and ROE drops to ~8.5% once the equity base roughly doubles post-raise. The land revaluation makes P/BV look cheaper; stripping it out, it is not. Natural live comparables are IDX-listed med-device names IRRA and OMED, whose current multiples should be pulled at publication date before any relative cheap/expensive judgement.

Bottom line

EMMI offers real growth, a genuine sector tailwind (≈8.68% market CAGR to 2030, plus JKN and TKDN support), credible principals, better underwriting than recent small-cap peers, and ~Rp81 bn of SOPHI backlog for near-term visibility. Against that sits a concentrated and fragile core: ~96% government revenue with no recurring contracts, heavy leverage (interest at 46% of operating profit), chronic negative working capital, margin-dilutive growth, a book value and leverage profile flattered by a pre-IPO revaluation, no hard founder lock-up, and a demanding ~23–26× P/E. The structure is sensible for the working-capital engine it funds, but the margin of safety is thin — returns hinge on tender win-rate and collection discipline, and the risks run deeper than the headline growth suggests.